91 related articles for article (PubMed ID: 23410002)
1. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
Arnold T; Michlmayr A; Baumann S; Burghuber C; Pluschnig U; Bartsch R; Steger G; Gnant M; Bergmann M; Bachleitner-Hofmann T; Oehler R
Eur J Clin Invest; 2013 Mar; 43(3):286-91. PubMed ID: 23410002
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
4. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
Michlmayr A; Bachleitner-Hofmann T; Baumann S; Marchetti-Deschmann M; Rech-Weichselbraun I; Burghuber C; Pluschnig U; Bartsch R; Graf A; Greil R; Allmaier G; Steger G; Gnant M; Bergmann M; Oehler R
Br J Cancer; 2010 Oct; 103(8):1201-8. PubMed ID: 20877360
[TBL] [Abstract][Full Text] [Related]
5. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer.
Taucher S; Rudas M; Mader RM; Gnant M; Sporn E; Dubsky P; Roka S; Bachleitner T; Fitzal F; Kandioler D; Wenzel C; Steger GG; Mittlböck M; Jakesz R
Breast Cancer Res Treat; 2003 Dec; 82(3):207-13. PubMed ID: 14703068
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Espinosa E; Morales S; Borrega P; Casas A; Madroñal C; Machengs I; Illarramendi JA; Lizón J; Moreno JA; Belón J; Janáriz J; de la Puente M; Checa T; Mel JR; González Barón M
Cancer Chemother Pharmacol; 2004 Dec; 54(6):546-52. PubMed ID: 15316749
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
8. The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer.
Hirano A; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Okabe T; Kimura K; Kamimura M; Domoto K; Aiba M; Ogawa K
Anticancer Res; 2006; 26(1B):581-4. PubMed ID: 16739324
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Li XR; Liu M; Zhang YJ; Wang JD; Zheng YQ; Li J; Ma B; Song X
Med Oncol; 2011 Dec; 28 Suppl 1():S31-8. PubMed ID: 20844986
[TBL] [Abstract][Full Text] [Related]
10. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.
Tiezzi DG; Andrade JM; Ribeiro-Silva A; Zola FE; Marana HR; Tiezzi MG
BMC Cancer; 2007 Feb; 7():36. PubMed ID: 17324279
[TBL] [Abstract][Full Text] [Related]
11. Activity of combination chemotherapy, docetaxel and epirubicin as neoadjuvant therapy for women with breast cancer.
Tfayli A; Holter J; Bova A; Venkatappa S; Bullock S; Dooley W; Ozer H
Anticancer Res; 2006; 26(6C):4911-6. PubMed ID: 17214361
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.
Nishimura R; Rai Y; Matsuo F; Anan K; Hara S; Imamura S; Itoyanagi N; Kato M; Okido M; Kudaka M; Ishikawa E; Kamada Y; Watanabe R; Shirouzu M; Mitsuyama S; Takamatsu Y; Tamura K
Anticancer Res; 2012 Aug; 32(8):3259-65. PubMed ID: 22843900
[TBL] [Abstract][Full Text] [Related]
14. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Steger GG; Galid A; Gnant M; Mlineritsch B; Lang A; Tausch C; Rudas M; Greil R; Wenzel C; Singer CF; Haid A; Pöstlberger S; Samonigg H; Luschin-Ebengreuth G; Kwasny W; Klug E; Kubista E; Menzel C; Jakesz R;
J Clin Oncol; 2007 May; 25(15):2012-8. PubMed ID: 17513805
[TBL] [Abstract][Full Text] [Related]
15. [Feasibility of breast conservation surgery after neoadjuvant chemotherapy for breast cancer].
Zhou B; Yang DQ; Qiao XM; Tong FZ; Cao YM; Liu P; Liu HJ
Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):769-72. PubMed ID: 15949385
[TBL] [Abstract][Full Text] [Related]
16. [Comparative study of chemosensitivity and efficacy between pirarubicin and epirubicin in breast cancer].
Zang MF; Zhang YM; Zhi YH; Zhai Z; Zhang M; Gu F; Zhi XC
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1388-92. PubMed ID: 21756809
[TBL] [Abstract][Full Text] [Related]
17. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
Chow LW; Tung SY; Ng TY; Im SA; Lee MH; Yip AY; Toi M; Glück S
Expert Opin Investig Drugs; 2013 Mar; 22(3):299-307. PubMed ID: 23394482
[TBL] [Abstract][Full Text] [Related]
18. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]